Biogen Inc. $BIIB Stock Holdings Boosted by Brevan Howard Capital Management LP

Key Points

• Brevan Howard Capital Management LP boosted its Biogen stake by 149% in Q3, adding 20,055 shares to hold 33,511 shares worth about $4.694 million.
• Biogen beat quarterly EPS estimates with $1.99 and reported $2.28 billion in revenue (down 7.2% YoY), and set FY 2026 guidance of 15.25–16.25 EPS; the stock trades near $181.55 with a market cap of $26.64 billion.
• Analyst sentiment is mixed — 12 Buys vs. 15 Holds — giving Biogen an average rating of Hold and a consensus price target of $205.04.

Brevan Howard Capital Management LP increased its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 149.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,511 shares of the biotechnology company's stock after acquiring an additional 20,055 shares during the period. Brevan Howard Capital Management LP's holdings in Biogen were worth $4,694,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BIIB. Empowered Funds LLC increased its stake in shares of Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company's stock valued at $965,000 after purchasing an additional 2,777 shares during the period. Focus Partners Wealth raised its holdings in shares of Biogen by 172.2% during the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company's stock valued at $1,392,000 after buying an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Biogen during the second quarter worth approximately $216,000. Allworth Financial LP grew its stake in shares of Biogen by 114.3% in the second quarter. Allworth Financial LP now owns 2,179 shares of the biotechnology company's stock worth $274,000 after purchasing an additional 1,162 shares in the last quarter. Finally, Vise Technologies Inc. bought a new position in Biogen in the 2nd quarter valued at about $398,000. 87.93% of the stock is currently owned by institutional investors.

Biogen Price Performance

NASDAQ BIIB opened at $181.55 on Monday. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The business's fifty day moving average is $184.10 and its two-hundred day moving average is $167.19. The stock has a market capitalization of $26.64 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.44 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company's revenue was down 7.2% compared to the same quarter last year. During the same period last year, the company posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.18% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Citigroup raised their price objective on shares of Biogen from $185.00 to $215.00 and gave the company a "neutral" rating in a research note on Monday, February 9th. Canaccord Genuity Group upped their target price on Biogen from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Morgan Stanley set a $190.00 price target on Biogen in a research report on Sunday, February 8th. Stifel Nicolaus boosted their price objective on Biogen from $202.00 to $214.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Finally, UBS Group started coverage on Biogen in a report on Tuesday, January 6th. They issued a "neutral" rating and a $185.00 price objective for the company. Twelve equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Biogen currently has an average rating of "Hold" and a consensus target price of $205.04.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.